#United States #Washington #Supreme Court #Hikma Pharmaceuticals #icosapent ethyl

Hikma's Triumph at the Supreme Court

On June 4, 2026, Hikma Pharmaceuticals PLC, along with its subsidiary Hikma Pharmaceuticals USA Inc., expressed its satisfaction with the recent unanimous decision by the Supreme Court of the United States. This ruling effectively put an end to Amarin's patent infringement litigation against Hikma. The outcome is seen as a significant victory for the pharmaceutical company and the patients it serves.

A Commitment to Access and Affordability

Sam Park, Hikma's General Counsel, emphasized the company's long-standing commitment to ensuring that patients have access to high-quality, affordable medications. He stated, "Hikma has long fought for patients and their access to safe, high-quality, and affordable medicines. We welcome the United States Supreme Court's decision, which allows us to continue providing millions of American patients with generic medicines that improve health and save lives."

This ruling marks a pivotal moment for Hikma’s operations in the United States, particularly with regard to its generic version of the medication icosapent ethyl. This drug, derived from purified fish oil, is used to treat individuals suffering from severe hypertriglyceridemia—a condition characterized by high levels of triglycerides in the bloodstream. In 2020, Hikma received FDA approval to launch its own version of Amarin's branded icosapent, Vascepa®, known in legal terms as a "skinny label" because it only covers non-patented uses of the medicine.

Background of the Dispute

The legal battle began when Amarin accused Hikma of marketing its generic version for both patented and non-patented uses, a claim that Hikma vehemently denied. Initially, a U.S. district court dismissed Amarin's lawsuit; however, this decision was later overturned by a federal appeals court, thus allowing Amarin's claims to proceed. In response, Hikma took the matter to the Supreme Court, hoping to ensure that patients retain access to generic alternatives for essential medications.

Park reiterated the importance of the Supreme Court's decision by highlighting that it safeguards the availability of generic medicines. "Hikma took this fight to the Supreme Court to ensure patients have ongoing access to generic medicines, especially those medicines that have appropriately carved out patented indications. Amarin's lawsuit sought to limit legitimate generic competition, despite long-established legal frameworks governing generic medicines in the U.S. We are very pleased the U.S. Supreme Court has ended this litigation, which will have a beneficial impact on all Americans," he stated.

A Global Commitment to Health

Hikma Pharmaceuticals has been dedicated to improving health outcomes for over 45 years, operating as a global company with a strong local presence across North America, the Middle East, North Africa (MENA), and Europe. Aiming to bridge the gap between cutting-edge scientific discoveries and practical healthcare solutions, Hikma has developed a broad range of generic and branded medicines. With over 9,400 employees globally, the company's commitment continues to resonate across various communities.

Hikma not only focuses on generic medications; through its venture capital arm, it supports innovative health technologies that aim to transform the landscape of healthcare. These initiatives reflect its dedication to serving patients and healthcare providers alike while enhancing the overall quality of life.

For more information, you can visit Hikma's official website.